Skip to main content
. Author manuscript; available in PMC: 2012 Jan 5.
Published in final edited form as: Clin Exp Metastasis. 2007 Dec 5;25(2):109–118. doi: 10.1007/s10585-007-9126-2

Figure 3. Absence of SPARC does not affect prostate cancer progression or metastasis.

Figure 3

(A) Average urogenital masses of TRAMP− (left, p = 0.44) or TRAMP+ animals (right, p = 0.75) did not differ between genotypes. (B) The incidence of palpable prostate carcinomas and macroscopic para-aortic/lumbar lymph node metastases did not differ between the two cohorts. (C) Disease progression also did not differ between SPARC+/− and SPARC−/− tumors, as assessed by histological grading of the individual dorsolateral (DL) and ventral (VN) prostate lobes. (D) When an overall highest grade was assigned to each prostate sample (identical to the highest grade given to any constituent lobe), no significant differences were observed between genotypes in the distribution of grades awarded.